الفهرس 
The potential use of metabolomic fingerprinting for therapeutic assessment of new compounds in a diabetic animal model
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 227 |  |  |
| | | from | 227 | | |
Abstract
Diabetes is considered one of the most important health emergencies worldwide andEgypthas8.2milliondiabeticpatientsaccordingtotheInternationalDiabetes Federationreportin2017.Theaimofthisstudywastoinvestigatethetime-course variation in the metabolic profile between negative control and positive control (diabetic) rats to detect urinary metabolic biomarkers using the metabolomics approach for the evaluation of the therapeutic efficacy of novel anti-diabetic drugs. The study was conducted on a positive control, a negative control, vildagliptin-treated group, glibenclamide-treated group and tested drug-treated groups.Type 2 diabetes was induced in male Wistar albino rats using 10% fructose in drinking water for 3 weeks followed by a single I.P injection of 40 mg/Kg streptozotocin. After the induction of diabetes, the tested drug-treated groups were administered two newly synthesized DPP-4 inhibitors, N’-(3- chlorobenzylidene)-5,6,7,8-tetrahydronaphthalene-2-sulfonohydrazide (100 mg/Kg, daily) and N’-((1H-indol-3-yl) methylene)-5,6,7,8- tetrahydronaphthalene-2-sulfonohydrazide, (200 mg/Kg, daily).Then, urine was collected during 24 hrs from rats at 3 time points (0, 2 and 4 weeks after confirmation of diabetes), and analyzed by GC-MS and H1NMR, followed by multivariate data analysis. The results from H1NMR pointed out that D-glucose, taurine, L-carnitine, L-fucose,1,5-anhydrosorbitol and D-galactose levels showed consistent significant variation (P < 0.05) between positive and negative controls during the whole experimental period that we cannot dependonlyonglucoselevelsaloneforprognosticpurposessincethereareother metabolic disturbances in diabetes which need to be tracked for better disease prognosis